// App-Quantinova.ai

2587 : Trial in Progress: The Phase III, Randomized, Open-Label, Multicenter COMMODORE 1 Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Adult and Adolescent Patients with Paroxysmal Nocturnal Hemoglobinuria Currently Treated with Complement Inhibitors

Researchers

Presenter

  • Antonio Risitano

Principal Investigators

  • Alexander Rth

  • Austin G Kulasekararaj

  • Jeffrey Pu

  • Jun-ichi Nishimura

  • Lilyan Wright

  • Anita Appius

  • Alexandre Sostelly

  • Sasha Sreckovic

  • Charlotte Vignal

  • Talha Munir

Medical Centers

  • Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy

  • Hematology and BMT Unit,AORN Moscati Avellino,Avellino,Italy

  • Department of Dermatology, University Hospital, University Duisburg-Essen, Essen, Germany

  • Department of Haematological Medicine,King’s College Hospital‐NHS Foundation Trust, NIHR Wellcome Foundation Clinical Research Facility, King’s College London,London,United Kingdom

  • Hollings Cancer Center, Medical University of South Carolina, Charleston, SC

  • Department of Pathologic Oncology, Mie University Graduate School of Medicine, Mie, Japan

  • Genentech, San Francisco, CA

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • St. James's University Hospital, Leeds, United Kingdom

Locations

  • Italy

  • Germany

  • United Kingdom

  • United States

  • Japan

  • Switzerland

Companies

  • F. Hoffmann-La Roche

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Paroxysmal nocturnal hemoglobinuria

Biomarkers

  • Lactate dehydrogenase

Drug/Treatment

  • Eculizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Pharmacokinetics

  • Open Label

  • Non Inferiority

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • NCT03157635

  • NCT04432584

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved